|Type 1 Diabetes|
|Business Reports - Market Report|
Type 1 Diabetes - Drug Pipeline Assessment and Market Forecasts to 2017
GlobalData, the industry analysis specialist, has released a new report, "Type 1 Diabetes - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global type 1 diabetes market. The report identifies the key trends shaping and driving the global type 1 diabetes market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global type 1 diabetes sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
The Type 1 Diabetes Therapeutics Market is Forecast to Show Moderate Growth until 2017
GlobalData estimated the global type 1 diabetes therapeutics market to be valued at $2.7 billion in 2009. It is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.1% to reach $4.4 billion by 2017. This growth is primarily attributed to an increase in the average cost of therapy with the existing treatment options and an increased treatment seeking rate. Novo Nordisk and Eli Lilly remain the market leaders within the global type 1 diabetes therapeutics market.
Increase in Average Cost of Therapy Will be the Key Driver of the Market, Followed by Increased Treatment Seeking
The prevalence rate for type 1 diabetes globally was 0.6% and this amounted to approximately 4.2 million people in 2009. Type 1 diabetes is an autoimmune condition and is generally found in young adults and children. The number of people with type 1 diabetes is estimated to increase at a slower rate of 1.2% between 2009 and 2017. The number of type 1 diabetes patients increased at a higher rate of 1.5% during the period 2001-2009. Therefore, the increase in the average cost of therapy will be the key to growth in the market. The average cost of therapy is expected to increase at a CAGR of 4.5% over the period 2009-2017. The increase in the average cost of therapy will be primarily driven by the higher cost of insulin analogs. The increase in awareness about type 1 diabetes due to awareness programs held in key countries will continue to improve the treatment seeking behavior. The increase in people who seek treatment could lead to an increase in the prescription population, made possible by the effective diagnosis tests currently available in the market.
The Current Competition is Strong Due to the Presence of Products with Similar Efficacy and a Lack of Generics in the Market
The current market is dominated by insulin and insulin analog products. These products have similar efficacy and safety profiles with only marginal differences. This has increased the competition further in the market. The manufacturers are forced to compete on pricing or on improving the dosage requirements of their currently marketed products. In addition, the presence of a few promising drugs such as Oral-lyn and monoclonal antibodies in the late stage pipeline means that the competition will increase further once these products are successfully launched in the market. The current market also lacks any generic insulin product despite two insulin products losing patent protection. This is because of the lack of proper guidelines for the introduction of biogenerics. In Europe, where guidelines for the approval of biosimilars exist, an application for an insulin biosimilar was filed by Marvel LifeSciences. This was later withdrawn as it did not meet the required guidelines.
The Type 1 Diabetes Therapeutics Market Has Moderate Unmet Need Especially with Regard to Drug Safety
The type 1 diabetes therapeutics market has unmet needs in terms of both efficacy and safety. These unmet needs imply that the market is not served by the existing drugs completely. The market has moderate scope available to new entrants that could capture value from the under-served segments. The efficacy of the current product offerings in the type 1 diabetes therapeutics market is moderate as there is no cure for the disease. However, the current products are able to achieve better glucose control in the majority of cases. This process of controlling diabetes-related symptoms is generally painful and requires strict compliance to a treatment regime. The current products available are relatively inconvenient in terms of the mode of delivery, which impacts patient compliance. All the products in the market show adverse reactions such as hypoglycemia, local injection site reactions and allergic reactions. These adverse reactions indicate that none of the products offer a completely safe profile. Therefore the market also faces unmet need in terms of the safety of products. With the exception of human insulin such as Humulin and Novolin, the other insulin products (insulin analogs) are relatively highly priced. This increases the average cost of therapy for these analogs.
For further details, visit: www.globaldata.com/reportstore.Read also at Pharmaceutical Licensing Network
Newer news items
|< Prev||Next >|
Membership at Farmavita.Net is Free
Register yourself and connect with community of 600+ pharmaceutical executives, researchers and innovators. Expand your professional network and find new business and career development opportunities.
Click here for registration!